ALNY Overview
Upcoming Projects (ALNY)
-
Don’t see a project related to the company you care about? Create your own!
Executed Projects (ALNY)
-
A Second Look: Digging into the data presented at AHA 2024 on nexiguran ziclumeran and Nucresiran in patients with ATTR-CM
Tickers: NTLA, ALNY
Executed On: Dec 19, 2024 at 12:00 PM EST -
Digging into the data presented at AHA 2024 on nexiguran ziclumeran and Nucresiran in patients with ATTR-CM
Tickers: NTLA, ALNY
Executed On: Dec 06, 2024 at 04:00 PM EST -
A Second View: Digging into the data presented at AHA 2024 on nexiguran ziclumeran and Nucresiran in patients with ATTR-CM
Tickers: NTLA, ALNY
Executed On: Dec 05, 2024 at 03:30 PM EST -
A second look: Revisiting the HELIOS-B data for vutrisiran in ATTR-CM following publication in NEJM and presentation at ESC
Tickers: ALNY, BBIO, PFE
Executed On: Oct 22, 2024 at 03:00 PM EDT -
A third look: Revisiting the HELIOS-B data for vutrisiran in ATTR-CM following publication in NEJM and presentation at ESC
Tickers: ALNY, BBIO, PFE
Executed On: Oct 15, 2024 at 05:00 PM EDT -
Revisiting the HELIOS-B data for vutrisiran in ATTR-CM following publication in NEJM and presentation at ESC
Tickers: ALNY, BBIO, PFE
Executed On: Sep 12, 2024 at 12:30 PM EDT -
A third look at Alnylam's vutrisiran and the positive topline results from the HELIOS-B Phase 3 study in patients with ATTR amyloidosis with cardiomyopathy (ATTR-CM).
Ticker: ALNY
Executed On: Jul 12, 2024 at 07:00 AM EDT -
A second look at Alnylam's vutrisiran and the positive topline results from the HELIOS-B Phase 3 study in patients with ATTR amyloidosis with cardiomyopathy (ATTR-CM).
Ticker: ALNY
Executed On: Jul 09, 2024 at 04:00 PM EDT -
A look at Alnylam's vutrisiran and the positive topline results from the HELIOS-B Phase 3 study in patients with ATTR amyloidosis with cardiomyopathy (ATTR-CM).
Ticker: ALNY
Executed On: Jul 02, 2024 at 10:30 AM EDT -
A Third Look: Discussing the KARDIA-2 Topline Study Results of Zilebesiran, an investigational, subcutaneously administered RNAi therapeutic in development by Alnylam for the treatment of hypertension
Ticker: ALNY
Executed On: Mar 18, 2024 at 09:30 AM EDT -
Discussing the KARDIA-2 Topline Study Results of Zilebesiran, an investigational, subcutaneously administered RNAi therapeutic in development by Alnylam for the treatment of hypertension
Ticker: ALNY
Executed On: Mar 13, 2024 at 12:30 PM EDT -
A Third look: Discussing the FDA's rejection of ONPATTRO (patisiran) for the treatment of patients with ATTR-CM.
Ticker: ALNY
Executed On: Nov 28, 2023 at 08:00 AM EST -
A Second look: Discussing the FDA's rejection of ONPATTRO (patisiran) for the treatment of patients with ATTR-CM.
Ticker: ALNY
Executed On: Nov 01, 2023 at 11:00 AM EDT -
Discussing the FDA's rejection of ONPATTRO (patisiran) for the treatment of patients with ATTR-CM.
Ticker: ALNY
Executed On: Oct 17, 2023 at 10:00 AM EDT -
A third look: Discussing the potential of Zilebesiran, an inhibitor of hepatic angiotensinogen synthesis, in development by Alnylam Pharmaceuticals as an injection for patients with hypertension.
Ticker: ALNY
Executed On: Sep 15, 2023 at 10:00 AM EDT -
A Third Look: Discussing the standard of care for Alzheimer's Disease and the potential of Alnylam Pharmaceuticals ALN-APP
Tickers: ALNY, BIIB, QTRX, DGX
Executed On: Sep 13, 2023 at 05:30 PM EDT -
A Second Look: Discussing the standard of care for Alzheimer's Disease and the potential of Alnylam Pharmaceuticals ALN-APP
Tickers: ALNY, BIIB, QTRX, DGX
Executed On: Sep 08, 2023 at 05:00 PM EDT -
Discussing the standard of care for Alzheimer's Disease and the potential of Alnylam Pharmaceuticals ALN-APP
Tickers: ALNY, QTRX, BIIB, DGX
Executed On: Aug 09, 2023 at 12:00 PM EDT -
A second look: Discussing the potential of Zilebesiran, an inhibitor of hepatic angiotensinogen synthesis, in development by Alnylam Pharmaceuticals as an injection for patients with hypertension.
Ticker: ALNY
Executed On: Aug 08, 2023 at 02:00 PM EDT -
Discussing the potential of Zilebesiran, an inhibitor of hepatic angiotensinogen synthesis, in development by Alnylam Pharmaceuticals as an injection for patients with hypertension.
Ticker: ALNY
Executed On: Jul 26, 2023 at 01:00 PM EDT -
A Third Look: Discussing the treatment landscape and the potential of Patisiran in patients with ATTR-CM in light of the recent data presented from the 18 months result of the APOLLO-B Phase 3 Study.
Ticker: ALNY
Executed On: Jun 07, 2023 at 03:00 PM EDT -
A Second Look: Discussing the treatment landscape and the potential of Patisiran in patients with ATTR-CM in light of the recent data presented from the 18 months result of the APOLLO-B Phase 3 Study.
Ticker: ALNY
Executed On: Jun 05, 2023 at 06:00 PM EDT -
Discussing the treatment landscape and the potential of Patisiran in patients with ATTR-CM in light of the recent data presented from the 18 months result of the APOLLO-B Phase 3 Study.
Ticker: ALNY
Executed On: Jun 02, 2023 at 11:00 AM EDT -
Discussing the current treatment landscape for Primary Hyperoxaluria type 1 and the potential of Oxlumo(lumasiran) in patients with PH1 and advanced kidney dysfunction.
Ticker: ALNY
Executed On: Oct 21, 2022 at 05:00 PM EDT -
A fourth look: Discussing the potential of Patisiran in patients with ATTR Amyloidosis with Cardiomyopathy based on the recent data presented from the APOLLO-B Phase 3 Study
Tickers: ALNY, PFE
Executed On: Oct 21, 2022 at 10:30 AM EDT -
A third look: Discussing the potential of Patisiran in patients with ATTR Amyloidosis with Cardiomyopathy based on the recent data presented from the APOLLO-B Phase 3 Study
Tickers: ALNY, PFE
Executed On: Oct 13, 2022 at 04:00 PM EDT -
A second look: Discussing the potential of Patisiran in patients with ATTR Amyloidosis with Cardiomyopathy based on the recent data presented from the APOLLO-B Phase 3 Study
Tickers: ALNY, IONS, PFE
Executed On: Oct 12, 2022 at 02:00 PM EDT -
Discussing the potential of Patisiran in patients with ATTR Amyloidosis with Cardiomyopathy based on the recent data presented from the APOLLO-B Phase 3 Study
Ticker: ALNY
Executed On: Oct 07, 2022 at 09:15 AM EDT -
A Second View: Discussing the use of Cemdisiran in patients with Immunoglobulin A Nephropathy (IgAN)
Tickers: ALNY, REGN
Executed On: Aug 22, 2022 at 10:00 AM EDT -
A second look:Discussing ALNY Topline Results from APOLLO-B Phase 3 Study of Patisiran in Patients with ATTR Amyloidosis with Cardiomyopathy
Ticker: ALNY
Executed On: Aug 18, 2022 at 02:00 PM EDT -
Discussing ALNY Topline Results from APOLLO-B Phase 3 Study of Patisiran in Patients with ATTR Amyloidosis with Cardiomyopathy
Ticker: ALNY
Executed On: Aug 09, 2022 at 01:00 PM EDT -
Discussing the use of Cemdisiran in patients with Immunoglobulin A Nephropathy (IgAN)
Tickers: ALNY, REGN
Executed On: Jul 22, 2022 at 09:00 AM EDT -
Discussing Vutrisiran in Patients with hATTR Amyloidosis with Polyneuropathy
Ticker: ALNY
Executed On: Apr 05, 2022 at 09:00 AM EDT
Upcoming & Overdue Catalysts (ALNY)
-
Don’t see a catalyst related to the company you care about? Create your own!
Strategic Initiatives (ALNY)
-
Don’t see a strategic initiative related to the company you care about? Create your own!
